New Whole Animal ELISA for Angiogenic Drug Screening

描述（由申请人提供）：本研究的总体目标是开发一种快速，定量的体内检测格式，用于筛选血管生成候选药物，使用斑马鱼作为模式生物。血管生成是一个重要的生物学过程，涉及多种病理情况，包括癌症、糖尿病视网膜病变、黄斑变性、缺血性心脏病、外周动脉疾病和伤口愈合受损。然而，缺乏对血管生成的生物学基础的了解以及缺乏检测和动物模型阻碍了药物的开发。提出的斑马鱼试验的一个显著优点是，在复杂的生理环境中评估化合物的治疗潜力，其通量比哺乳动物体内生物测定高得多。使用基于细胞的屏幕是不可能获得这些信息的。公共卫生相关性：血管生成已被证明与几种严重疾病有关，包括糖尿病、癌症、心脏病和黄斑变性。该SBIR旨在开发一种基于斑马鱼微孔板的高通量体内定量检测方法，以评估潜在治疗方法的血管生成效果。

DESCRIPTION (provided by applicant): The overall goal of this research is to develop a rapid, quantitative in vivo assay format for screening angiogenic drug candidates using zebrafish as a model organism. Angiogenesis is well established as a major biological process involved in several pathological conditions, including cancer, diabetic retinopathy, macular degeneration, ischemic heart disease, peripheral arterial disease, and impaired wound healing. However, the lack of understanding of the biological basis of angiogenesis and the lack of assays and animal models have hampered drug development. A significant advantage of the proposed zebrafish assay is that the therapeutic potential of a compound is evaluated in a complex physiological environment with much higher throughput than mammalian in vivo bioassays. Using cell-based screens, this information is impossible to obtain. PUBLIC HEALTH RELEVANCE: Angiogenesis has been shown to be involved in several serious diseases, including diabetes, cancer, heart disease and macular degeneration. This SBIR aims to develop a high throughput quantitative in vivo zebrafish microplate based assay for evaluating angiogenic effects of potential therapeutics.